Perspective Therapeutics (NYSEAMERICAN:CATX) Upgraded by BMO Capital Markets to “Strong-Buy” Rating

BMO Capital Markets upgraded shares of Perspective Therapeutics (NYSEAMERICAN:CATX) to a strong-buy rating in a research note issued to investors on Tuesday morning,Zacks.com reports.

Other equities research analysts have also issued research reports about the company. Wedbush reaffirmed an “outperform” rating and set a $11.00 price target on shares of Perspective Therapeutics in a research report on Tuesday, May 5th. BTIG Research reissued a “buy” rating on shares of Perspective Therapeutics in a research note on Friday, July 24th. Piper Sandler dropped their target price on shares of Perspective Therapeutics from $16.00 to $14.00 and set an “overweight” rating on the stock in a report on Tuesday, August 11th. Finally, Bank of America cut their price target on shares of Perspective Therapeutics from $6.00 to $5.00 and set a “neutral” rating on the stock in a research note on Friday, August 14th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, Perspective Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $11.50.

Perspective Therapeutics Price Performance

Shares of CATX stock opened at $3.48 on Tuesday. Perspective Therapeutics has a 12-month low of $1.96 and a 12-month high of $6.16. The firm has a fifty day moving average of $3.10 and a 200-day moving average of $3.95.

Perspective Therapeutics (NYSEAMERICAN:CATX) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.03. The business had revenue of $0.08 million for the quarter, compared to the consensus estimate of $0.09 million. Perspective Therapeutics had a negative return on equity of 41.92% and a negative net margin of 28,467.97%. Equities analysts predict that Perspective Therapeutics will post -1.03 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of CATX. Commodore Capital LP bought a new stake in Perspective Therapeutics in the 1st quarter valued at approximately $26,424,000. Avidity Partners Management LP grew its stake in shares of Perspective Therapeutics by 88.4% during the 1st quarter. Avidity Partners Management LP now owns 6,049,999 shares of the company’s stock worth $25,228,000 after acquiring an additional 2,839,266 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Perspective Therapeutics by 5.0% in the third quarter. Vanguard Group Inc. now owns 3,437,865 shares of the company’s stock valued at $11,792,000 after purchasing an additional 163,532 shares during the last quarter. Affinity Asset Advisors LLC lifted its position in shares of Perspective Therapeutics by 954.9% in the first quarter. Affinity Asset Advisors LLC now owns 3,164,582 shares of the company’s stock worth $13,196,000 after purchasing an additional 2,864,582 shares in the last quarter. Finally, Spruce Street Capital LP bought a new stake in shares of Perspective Therapeutics in the first quarter worth $10,955,000. 54.66% of the stock is currently owned by institutional investors.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.